Close
Smartlab Europe
Achema middle east

Press Releases

AARDEX and Cambridge Cognition Join Forces to Bring Next-Level Adherence Oversight to Hybrid and Decentralized Clinical Trials

Adherence specialists AARDEX Group and remote research platform experts in the Clinpal team at Cambridge Cognition have teamed up to provide next-level adherence monitoring during hybrid and decentralized clinical trials (DCTs). Integrating AARDEX Group’s MEMS® dosing capture and analytics system with Cambridge...

Pharmapack Europe Awards Winners 2023

Pharmapack Europe (#PharmapackEU) announces the winners of the prestigious 2023 Pharmapack Awards spanning five categories across two dedicated awards. The Health Product Awards are open to the entire pharma industry – and include two categories for ‘eco-design’ and ‘patient-centric design’...

Glyconics©’ novel non-invasive diabetes screening device meets primary endpoints in two clinical investigations

Award-winning medtech firm, Glyconics© has successfully completed two independent clinical studies to validate the performance and safety of its novel non-invasive diabetes screening device. The currently embargoed ANODE01 and ANODE02 diabetes programme results will be formally announced at the annual...

Pharmapack Drug Delivery Index hits record high

Pharmapack Europe 2023 (February 1-2) opens at Paris Expo, Porte de Versailles (Hall 7.2) with more than 5,500 attendees and over 300 companies expected as a new report and survey points to a dramatic transformation in the industry’s outlook. The Pharmapack 2023 report’s key metric, the...

Andelyn Biosciences and Odylia Therapeutics Partner to Manufacture Novel Gene Therapy for Vision Loss

Andelyn Biosciences, Inc., a pioneering and patient-focused gene therapy Contract Development and Manufacturing Organization (CDMO), has partnered with Odylia Therapeutics, a nonprofit 501(c)(3) biotech focused on accelerating rare disease drug development, to manufacture a novel gene therapy (OT-004) to...

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus Vaccine Candidate

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced mRNA-1345, an investigational mRNA vaccine candidate for respiratory syncytial virus (RSV), has been granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration (FDA) for the...

Catalent Launches New Service for End-to-End Supply Chain Case Management of Cell and Gene Therapies

Catalent, the leader in enabling the development and supply of better treatments for patients worldwide, announced the launch of its new Case Management Service, which has been specifically designed to address the unique challenges associated with the safe and...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »